X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glenmark Pharma Fact Sheet, Glenmark Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Fact Sheet   (GLPH)

Here is the latest financial fact sheet of Glenmark Pharma. For more details, see the Glenmark Pharma quarterly results and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

GLENMARK PHARMA Price History

Price Rs 599.5
Mkt Cap Rs m 162,632
Vol '000 12.7
P/E X 13.6
P/CF X 16.7
EPS (TTM) Rs 44.1
% ch % 0.1
No. of shares m 271.28
% ch week % -1.9
% ch 1-mth % -2.3
% ch 12-mth % -35.8
52 week H/L Rs 993.0/568.0
(As on Oct 24, 2017 11:18:00 AM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

GLENMARK PHARMA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
GLENMARK PHARMA EQUITY SHARE DATA
High Rs3515516128791,262 
Low Rs263301464752672 
Sales per share (Unadj.) Rs148.6185.1221.4244.4270.6 
Earnings per share (Unadj.) Rs17.223.220.117.524.9 
Diluted earnings per shareRs17.123.220.117.525.9 
Cash flow per share (Unadj.) Rs20.827.928.127.134.4 
Dividends per share (Unadj.) Rs2.002.002.002.002.00 
Adj. dividends per shareRs1.992.002.002.002.08 
Dividend yield (eoy) %0.70.50.40.20.2 
Book value per share (Unadj.) Rs88.8102.0110.0110.6151.3 
Adj. book value per shareRs88.5101.9110.0110.6157.4 
Shares outstanding (eoy) m270.53270.85271.22271.29282.16 
Bonus/Rights/Conversions  ESOS---- 
Price / Sales ratio x2.12.32.43.33.6 
Avg P/E ratio x17.918.426.746.638.9 
P/CF ratio (eoy) x14.815.319.130.128.1 
Price / Book Value ratio x3.54.24.97.46.4 
Dividend payout %11.78.69.911.48.0 
Avg Mkt Cap Rs m83,053115,355145,889221,284272,778 
No. of employees `000NANANA9.510.0 
Total wages/salary Rs m6,2897,83010,26212,02413,782 
Avg. sales/employee Rs ThNMNMNM6,961.17,614.9 
Avg. wages/employee Rs ThNMNMNM1,262.51,374.8 
Avg. net profit/employee Rs ThNMNMNM499.0700.2 
GLENMARK PHARMA INCOME DATA
Net Sales Rs m40,20650,12360,05266,29876,340 
Other income Rs m182108115219356 
Total revenues Rs m40,38850,23160,16766,51676,696 
Gross profit Rs m7,14410,15310,90810,22514,172 
Depreciation Rs m9791,2702,1682,6002,691 
Interest Rs m1,4661,6001,8861,9021,789 
Profit before tax Rs m4,8817,3906,9695,94310,048 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m2381,1071,5131,1903,028 
Profit after tax Rs m4,6436,2835,4564,7527,019 
Gross profit margin %17.820.318.215.418.6 
Effective tax rate %4.915.021.720.030.1 
Net profit margin %11.512.59.17.29.2 
GLENMARK PHARMA BALANCE SHEET DATA
Current assets Rs m29,47237,26847,62753,23359,096 
Current liabilities Rs m19,01722,01429,49237,11340,018 
Net working cap to sales %26.030.430.224.325.0 
Current ratio x1.51.71.61.41.5 
Inventory Days Days7261577075 
Debtors Days Days113119131138119 
Net fixed assets Rs m24,24827,68230,35732,70439,075 
Share capital Rs m271271271271282 
"Free" reserves Rs m15,78919,33821,41517,56330,281 
Net worth Rs m24,01627,63029,83330,00342,703 
Long term debt Rs m13,12519,20324,28725,74424,873 
Total assets Rs m54,66071,71086,33696,875111,026 
Interest coverage x4.35.64.74.16.6 
Debt to equity ratio x0.50.70.80.90.6 
Sales to assets ratio x0.70.70.70.70.7 
Return on assets %11.211.08.56.97.9 
Return on equity %19.322.718.315.816.4 
Return on capital %17.119.216.414.117.5 
Exports to sales %13.411.911.744.843.3 
Imports to sales %0.91.71.07.17.4 
Exports (fob) Rs m5,4065,9577,03929,72033,044 
Imports (cif) Rs m3478585794,6805,672 
Fx inflow Rs m5,6627,0078,52831,29936,945 
Fx outflow Rs m2,3644,1353,64110,85661,066 
Net fx Rs m3,2982,8724,88820,443-24,122 
GLENMARK PHARMA CASH FLOW
From Operations Rs m 8,044 6,479 8,537 4,817 3,449 
From Investments Rs m -2,778 -4,641 -3,681 -5,400 -8,802 
From Financial Activity Rs m -3,614 1,952 -980 1,992 6,986 
Net Cashflow Rs m 1,252 2,851 1,896 -311 934 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 48.3%
Foreign collaborators 0.0%
Indian inst/Mut Fund 6.9%
FIIs 34.4%
ADR/GDR 0.0%
Free float 10.5%
Shareholders 56,727
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026
E-MAIL complianceofficer@glenmarkpharma.com WEB www.glenmarkpharma.com
TELEPHONE (022) 4018 9999 FAX (022) 4018 9986
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computer, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Walker, Chandiok & Co.
CHM: Glenn Saldanha (MD) COMP SEC: Sanjay Kumar Chowdhary YEAR OF INC: 1977 BSE CODE: 532296 FV (Rs): 1 DIV YIELD (%): 0.3

More Pharmaceuticals Company Fact Sheets:   SANOFI INDIA  ORCHID PHARMA LTD  GSK PHARMA  SUVEN LIFE  NOVARTIS  

Compare GLENMARK PHARMA With:   SANOFI INDIA  ORCHID PHARMA LTD  GSK PHARMA  SUVEN LIFE  NOVARTIS  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; ONGC & HUL Top Gainers(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.17% while the Hang Seng is up 0.10%.

Views on news

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Rs 71 Trillion Business Could Make or Break (Your) Wealth in the Next Decade(The 5 Minute Wrapup)

Oct 17, 2017

How to profit from behavioral biases afflicting the industry.

Electric Vehicles: The Final Piece of the Puzzle(Smart Contrarian)

Oct 16, 2017

Just as there would be gainers from an electric vehicles boom, who possibly could be the biggest losers.

The Delusional Optimism of India's Real Estate Companies(Vivek Kaul's Diary)

Oct 16, 2017

This is a sector which hasn't gone anywhere in nearly six years, but those who run it continue to remain optimistic.

How Many Shares Should One Buy?(Daily Profit Hunter)

Oct 18, 2017

How much to buy is the biggest challenge after deciding what to buy. Here's your solution.

Companies Are Wary of Borrowing(Chart Of The Day)

Oct 17, 2017

How to profit from behavioral biases afflicting the industry.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2018
Get our special report, Multibagger Stocks Guide (2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - NOVARTIS COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS